Search Result

Results for "

Src-l1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Src (7) Autophagy (2) Bcr-Abl (2) Estrogen Receptor/ERR (1) FGFR (3) FXR (1) LIM Kinase (LIMK) (1) MAP3K (1) PDGFR (2) PROTACs (1) Ribosomal S6 Kinase (RSK) (1) VEGFR (2)
By Research Areas:	Cancer (7) Infection (1) Metabolic Disease (1)

Inhibitors & Agonists

Targets Recommended: Src SHP2

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

*Src Inhibitor 1* 10+ Cited Publications Src Kinase Inhibitor 1; Src-l1	Src	Cancer
Src Inhibitor 1 is a potent, ATP-competitive and selective dual site *Src* tyrosine kinase inhibitor with IC₅₀ values of 44 nM for Src and 88nM for Lck.

Ponatinib Maximum Cited Publications 26 Publications Verification AP24534	Bcr-Abl PDGFR VEGFR FGFR Src Autophagy	Cancer
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, *FGFR1, and Src*, respectively .

HY-101219

VEGFR-IN-1

VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC₅₀s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively .
HY-P2547

Tyrosine Kinase Peptide 1

Src Others

Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .
HY-16905

T338C Src-IN-1

T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).

VEGFR-IN-1
VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC₅₀s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, *Flt-1, c-Kit, EGF-R, and c-Src, respectively .*

Tyrosine Kinase Peptide 1	Src	Others
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .

T338C Src-IN-1
T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).

Ponatinib hydrochloride Maximum Cited Publications 26 Publications Verification AP24534 hydrochloride	Bcr-Abl FGFR PDGFR VEGFR Src Autophagy	Infection Cancer
Ponatinib hydrochloride (AP24534 hydrochloride) is a hydrochloride of ponatinib. Ponatinib is an orally active multi-targeted kinase inhibitor with IC₅₀s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, *FGFR1, and Src*, respectively .

1-NM-PP1 5+ Cited Publications PP1 Analog II	Src	Cancer
1-NM-PP1, a cell-permeable PP1 analog, is a potent Src family kinases inhibitor with IC₅₀s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively ^[1] .

ERRα antagonist-1	Estrogen Receptor/ERR	Cancer
ERRα antagonist-1 (Compound A) is a selective and high affinity estrogen-related receptor α (ERRα) antagonist. ERRα antagonist-1 inhibits interaction of ERRα with Proliferator-activated Receptor γ Coactivator-1α (PGC-1α) and PGC-1β, the IC₅₀ values are 170 nM and 180 nM, respectively. ERRα antagonist-1 does not inhibit the interaction of either ERRβ or ERRγ with PGC-1α and PGC-1β coactivator, and also does not inhibit interaction of ERα or ERβ with PGC-1α or SRC-1 ^[1].

ND1-YL2	PROTACs	Cancer
ND1-YL2 is a PROTAC that selectively degrades *SRC-1* via the N-degron pathway. ND1-YL2 significantly inhibits cancer invasion and migration in vitro and in vivo. ND1-YL2 can be used in cancer research ^[1].

BMS-986318	FXR	Metabolic Disease
BMS-986318 is a potent nonbile acid FXR agonist with EC₅₀s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis ^[1].

Osteogenic Growth Peptide (10-14) OGP(10-14); Historphin	Src	Others
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a *Src* inhibitor .

SM1-71	MAP3K Src FGFR Ribosomal S6 Kinase (RSK) LIM Kinase (LIMK)	Cancer
SM1-71 (compound 5) is a potent *TAK1* inhibitor, with a K_i of 160 nM, it also can covalently inhibit MKNK2, *MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1*, *FGFR1, ZAK (MLTK), MAP3K1, LIMK1* and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines ^[1] .

SRC-1 NR box peptide	Peptides	Others
SRC-1 NR box peptide is a biological active peptide. (This peptide is a 14-amino acid fragment from the steroid receptor cofactor SRC-1 NR II.)

Tyrosine Kinase Peptide 1	Src	Others
Tyrosine Kinase Peptide 1 is a control substrate peptide for c-Src assay .

Src Optimal Peptide Substrate	Peptides	Others
Src Optimal Peptide Substrate is a highly specific Src substrate. Src Optimal Peptide Substrate can used to measure the Src activity .

SRC-1 (686-700)	Peptides	Others
SRC-1 (686-700) is a biological active peptide. (This peptide is amino acids 686 to 700 fragment containing the second LXXLL motif, derived from NR box II of steroid receptor coactivator (SRC1). Coactivator proteins interact with nuclear receptors in a ligand-dependent manner and augment transcription.)

ND1-YL2	PROTACs	Cancer
ND1-YL2 is a PROTAC that selectively degrades *SRC-1* via the N-degron pathway. ND1-YL2 significantly inhibits cancer invasion and migration in vitro and in vivo. ND1-YL2 can be used in cancer research ^[1].

Osteogenic Growth Peptide (10-14) OGP(10-14); Historphin	Src	Others
Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a *Src* inhibitor .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Name
Email *

	Sorry, but the email address you supplied was invalid.